Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer

A California Cancer Consortium Trial

R. J. Morgan, T. W. Synold, D. Gandara, F. Muggia, S. Scudder, E. Reed, K. Margolin, J. Raschko, L. Leong, S. Shibata, M. Tetef, S. Vasilev, K. McGonigle, J. Longmate, Y. Yen, W. Chow, G. Somlo, M. Carroll, J. H. Doroshow

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. OC patients relapsing following platinum-based chemotherapy received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The pharmacokinetics of CSA and CBDCA were determined in a subset of patients. Thirty patients received 84 courses of therapy. Three partial responses were observed. Nine patients were stable for >4 months. Toxicity was similar to that observed in our previously reported phase I study and consisted of myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA level (high-performance liquid chromatographic assay [HPLC]) was 1109 ± 291 μg/mL (mean ± SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance. Steady-state levels of >1 μg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume17
Issue number2
DOIs
Publication statusPublished - Mar 1 2007
Externally publishedYes

Fingerprint

Carboplatin
Interferon-alpha
Ovarian Neoplasms
Cyclosporine
Area Under Curve
Neoplasms
Pharmacokinetics
Interferons
Platinum
Nausea
Vomiting
Headache
Creatinine
Drug Therapy

Keywords

  • Chemomodulation
  • Chemotherapy
  • Phase II

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology
  • Cancer Research

Cite this

Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer : A California Cancer Consortium Trial. / Morgan, R. J.; Synold, T. W.; Gandara, D.; Muggia, F.; Scudder, S.; Reed, E.; Margolin, K.; Raschko, J.; Leong, L.; Shibata, S.; Tetef, M.; Vasilev, S.; McGonigle, K.; Longmate, J.; Yen, Y.; Chow, W.; Somlo, G.; Carroll, M.; Doroshow, J. H.

In: International Journal of Gynecological Cancer, Vol. 17, No. 2, 01.03.2007, p. 373-378.

Research output: Contribution to journalArticle

Morgan, RJ, Synold, TW, Gandara, D, Muggia, F, Scudder, S, Reed, E, Margolin, K, Raschko, J, Leong, L, Shibata, S, Tetef, M, Vasilev, S, McGonigle, K, Longmate, J, Yen, Y, Chow, W, Somlo, G, Carroll, M & Doroshow, JH 2007, 'Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: A California Cancer Consortium Trial', International Journal of Gynecological Cancer, vol. 17, no. 2, pp. 373-378. https://doi.org/10.1111/j.1525-1438.2007.00787.x
Morgan, R. J. ; Synold, T. W. ; Gandara, D. ; Muggia, F. ; Scudder, S. ; Reed, E. ; Margolin, K. ; Raschko, J. ; Leong, L. ; Shibata, S. ; Tetef, M. ; Vasilev, S. ; McGonigle, K. ; Longmate, J. ; Yen, Y. ; Chow, W. ; Somlo, G. ; Carroll, M. ; Doroshow, J. H. / Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer : A California Cancer Consortium Trial. In: International Journal of Gynecological Cancer. 2007 ; Vol. 17, No. 2. pp. 373-378.
@article{67b0e6d78d08475d9d0bc0a6500c8024,
title = "Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: A California Cancer Consortium Trial",
abstract = "The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. OC patients relapsing following platinum-based chemotherapy received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The pharmacokinetics of CSA and CBDCA were determined in a subset of patients. Thirty patients received 84 courses of therapy. Three partial responses were observed. Nine patients were stable for >4 months. Toxicity was similar to that observed in our previously reported phase I study and consisted of myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA level (high-performance liquid chromatographic assay [HPLC]) was 1109 ± 291 μg/mL (mean ± SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance. Steady-state levels of >1 μg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination.",
keywords = "Chemomodulation, Chemotherapy, Phase II",
author = "Morgan, {R. J.} and Synold, {T. W.} and D. Gandara and F. Muggia and S. Scudder and E. Reed and K. Margolin and J. Raschko and L. Leong and S. Shibata and M. Tetef and S. Vasilev and K. McGonigle and J. Longmate and Y. Yen and W. Chow and G. Somlo and M. Carroll and Doroshow, {J. H.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1111/j.1525-1438.2007.00787.x",
language = "English",
volume = "17",
pages = "373--378",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer

T2 - A California Cancer Consortium Trial

AU - Morgan, R. J.

AU - Synold, T. W.

AU - Gandara, D.

AU - Muggia, F.

AU - Scudder, S.

AU - Reed, E.

AU - Margolin, K.

AU - Raschko, J.

AU - Leong, L.

AU - Shibata, S.

AU - Tetef, M.

AU - Vasilev, S.

AU - McGonigle, K.

AU - Longmate, J.

AU - Yen, Y.

AU - Chow, W.

AU - Somlo, G.

AU - Carroll, M.

AU - Doroshow, J. H.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. OC patients relapsing following platinum-based chemotherapy received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The pharmacokinetics of CSA and CBDCA were determined in a subset of patients. Thirty patients received 84 courses of therapy. Three partial responses were observed. Nine patients were stable for >4 months. Toxicity was similar to that observed in our previously reported phase I study and consisted of myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA level (high-performance liquid chromatographic assay [HPLC]) was 1109 ± 291 μg/mL (mean ± SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance. Steady-state levels of >1 μg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination.

AB - The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. OC patients relapsing following platinum-based chemotherapy received CBDCA area under the curve (AUC 3) with CSA and IFN, every 3 weeks. The pharmacokinetics of CSA and CBDCA were determined in a subset of patients. Thirty patients received 84 courses of therapy. Three partial responses were observed. Nine patients were stable for >4 months. Toxicity was similar to that observed in our previously reported phase I study and consisted of myelosuppression, nausea, vomiting, and headache. The mean end of infusion CSA level (high-performance liquid chromatographic assay [HPLC]) was 1109 ± 291 μg/mL (mean ± SD). CBDCA pharmacokinetics revealed a measured AUC of 3.61 versus a targeted AUC of 3, suggesting a possible effect of IFN on CBDCA levels versus errors in the estimation of CBDCA clearance using measured creatinine clearance. Steady-state levels of >1 μg/mL CSA (HPLC assay) are achievable in vivo. Insufficient clinical resistance reversal was observed in this study to warrant further investigation of this combination.

KW - Chemomodulation

KW - Chemotherapy

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=33947226126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947226126&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1438.2007.00787.x

DO - 10.1111/j.1525-1438.2007.00787.x

M3 - Article

VL - 17

SP - 373

EP - 378

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 2

ER -